Dren Bio, Inc.
http://www.drenbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dren Bio, Inc.
Deal Watch: BI Acquires Nerio For Novel Immune Checkpoint Inhibitor
Featuring deals involving Novartis/Dren, Palvella/Pieris, Eyenovia/Senju, Addex/Johnson & Johnson, Agilent/BioVectra, Meitheal/Nabriva, plus tech transfer agreements and deals in brief.
Finance Watch: Q4 Venture Financings Slumped But 2024 Outlook Is Optimistic
Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice